# Optimizing the Effectiveness of Selective Serotonin Reuptake Inhibitors (SSRIs) in Treatment-Resistant Depression

> **NCT00093847** · PHASE2 · COMPLETED · sponsor: **Massachusetts General Hospital** · enrollment: 73 (actual)

## Conditions studied

- Depression

## Interventions

- **DRUG:** S-adenosyl methione (SAMe)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00093847
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-05
- **Primary completion:** 2009-02
- **Final completion:** 2009-02
- **Target enrollment:** 73 (ACTUAL)
- **Last updated:** 2014-10-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00093847

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00093847, "Optimizing the Effectiveness of Selective Serotonin Reuptake Inhibitors (SSRIs) in Treatment-Resistant Depression". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00093847. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*